Participants were under observation upon release from index incarceration until return to custody, death or the study end date (31 December 2013).
Of the remaining participants (N = 1319), 721 (55%) were re-incarcerated during the study period and 598 (45%) were censored, either because of death (n = 25) or because they had not returned to prison by the study end date (n = 573).
Observation time was calculated from date of enrolment to study end date except where there was loss to follow up, diagnosis of TB, consent withdrawal or death.
Patients were followed from the date of IHD diagnosis, until diagnosis of dementia or depression, or censoring because of death, loss to follow-up, a subsequent procedure, or the study end date (March 31 , 2006.
Cohort members were followed from the latest of the study start date (January 1 , 1985, their 40th birthday or the date of immigration to Saskatchewan until the study end date (December 31, 2000), or the date of diagnosis of prostate cancer, death or emigration, whichever occurred first.
At the designated study end date, 15996.9595%).
Patients without a study end date and who were lost to follow-up were considered censored.
Three responses were received after the study end date and were excluded from analysis.
A total of 1,413 (25%) had died by the study end date.
We ascertained data on HPV vaccinations any time up to and including the study end date.
A small number of patients presenting to the ED were admitted to hospital prior to the study end date of 31 March 2008 but discharged after the study end date.
